These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 27358486)

  • 21. A genetic variant in long non-coding RNA MALAT1 associated with survival outcome among patients with advanced lung adenocarcinoma: a survival cohort analysis.
    Wang JZ; Xiang JJ; Wu LG; Bai YS; Chen ZW; Yin XQ; Wang Q; Guo WH; Peng Y; Guo H; Xu P
    BMC Cancer; 2017 Mar; 17(1):167. PubMed ID: 28253859
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An Integrated Prognostic Classifier for Stage I Lung Adenocarcinoma Based on mRNA, microRNA, and DNA Methylation Biomarkers.
    Robles AI; Arai E; Mathé EA; Okayama H; Schetter AJ; Brown D; Petersen D; Bowman ED; Noro R; Welsh JA; Edelman DC; Stevenson HS; Wang Y; Tsuchiya N; Kohno T; Skaug V; Mollerup S; Haugen A; Meltzer PS; Yokota J; Kanai Y; Harris CC
    J Thorac Oncol; 2015 Jul; 10(7):1037-48. PubMed ID: 26134223
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low expression of ITIH5 in adenocarcinoma of the lung is associated with unfavorable patients' outcome.
    Dötsch MM; Kloten V; Schlensog M; Heide T; Braunschweig T; Veeck J; Petersen I; Knüchel R; Dahl E
    Epigenetics; 2015; 10(10):903-12. PubMed ID: 26252352
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genome-scale meta-analysis of DNA methylation during progression of lung adenocarcinoma.
    Zhang QH; Dai XH; Dai ZM; Cai YN
    Genet Mol Res; 2015 Aug; 14(3):9200-14. PubMed ID: 26345853
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Validation of a proliferation-based expression signature as prognostic marker in early stage lung adenocarcinoma.
    Wistuba II; Behrens C; Lombardi F; Wagner S; Fujimoto J; Raso MG; Spaggiari L; Galetta D; Riley R; Hughes E; Reid J; Sangale Z; Swisher SG; Kalhor N; Moran CA; Gutin A; Lanchbury JS; Barberis M; Kim ES
    Clin Cancer Res; 2013 Nov; 19(22):6261-71. PubMed ID: 24048333
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role for High-Affinity IgE Receptor in Prognosis of Lung Adenocarcinoma Patients.
    Ly D; Zhu CQ; Cabanero M; Tsao MS; Zhang L
    Cancer Immunol Res; 2017 Sep; 5(9):821-829. PubMed ID: 28775209
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analytical validation of a proliferation-based molecular signature used as a prognostic marker in early stage lung adenocarcinoma.
    Warf MB; Fosso PG; Hughes E; Perry M; Brown KL; Reid JE; Kolquist KA; Wagner S; Gutin A; Roa B
    Biomark Med; 2015; 9(9):901-10. PubMed ID: 26158298
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Consensus of gene expression phenotypes and prognostic risk predictors in primary lung adenocarcinoma.
    Ringnér M; Staaf J
    Oncotarget; 2016 Aug; 7(33):52957-52973. PubMed ID: 27437773
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early2 factor (E2F) deregulation is a prognostic and predictive biomarker in lung adenocarcinoma.
    Chen L; Kurtyka CA; Welsh EA; Rivera JI; Engel BE; Muñoz-Antonia T; Yoder SJ; Eschrich SA; Creelan BC; Chiappori AA; Gray JE; Ramirez JL; Rosell R; Schabath MB; Haura EB; Chen DT; Cress WD
    Oncotarget; 2016 Dec; 7(50):82254-82265. PubMed ID: 27756884
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Elevated mRNA Levels of AURKA, CDC20 and TPX2 are associated with poor prognosis of smoking related lung adenocarcinoma using bioinformatics analysis.
    Zhang MY; Liu XX; Li H; Li R; Liu X; Qu YQ
    Int J Med Sci; 2018; 15(14):1676-1685. PubMed ID: 30588191
    [No Abstract]   [Full Text] [Related]  

  • 31. Immunodeficiency in Pancreatic Adenocarcinoma with Diabetes Revealed by Comparative Genomics.
    Yan Y; Gao R; Trinh TLP; Grant MB
    Clin Cancer Res; 2017 Oct; 23(20):6363-6373. PubMed ID: 28684632
    [No Abstract]   [Full Text] [Related]  

  • 32. Validation of a histology-independent prognostic gene signature for early-stage, non-small-cell lung cancer including stage IA patients.
    Der SD; Sykes J; Pintilie M; Zhu CQ; Strumpf D; Liu N; Jurisica I; Shepherd FA; Tsao MS
    J Thorac Oncol; 2014 Jan; 9(1):59-64. PubMed ID: 24305008
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A five-gene and corresponding protein signature for stage-I lung adenocarcinoma prognosis.
    Kadara H; Behrens C; Yuan P; Solis L; Liu D; Gu X; Minna JD; Lee JJ; Kim E; Hong WK; Wistuba II; Lotan R
    Clin Cancer Res; 2011 Mar; 17(6):1490-501. PubMed ID: 21163870
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1).
    Shimoji M; Shimizu S; Sato K; Suda K; Kobayashi Y; Tomizawa K; Takemoto T; Mitsudomi T
    Lung Cancer; 2016 Aug; 98():69-75. PubMed ID: 27393509
    [TBL] [Abstract][Full Text] [Related]  

  • 35. RhoB determines tumor aggressiveness in a murine EGFRL858R-induced adenocarcinoma model and is a potential prognostic biomarker for Lepidic lung cancer.
    Calvayrac O; Pradines A; Raymond-Letron I; Rouquette I; Bousquet E; Lauwers-Cances V; Filleron T; Cadranel J; Beau-Faller M; Casanova A; Milia J; Favre G; Mazières J
    Clin Cancer Res; 2014 Dec; 20(24):6541-50. PubMed ID: 25320360
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis.
    Thomas A; Chen Y; Steinberg SM; Luo J; Pack S; Raffeld M; Abdullaev Z; Alewine C; Rajan A; Giaccone G; Pastan I; Miettinen M; Hassan R
    Oncotarget; 2015 May; 6(13):11694-703. PubMed ID: 26028668
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of early-stage lung adenocarcinoma prognostic signatures based on statistical modeling.
    Wu C; Zhang D
    Cancer Biomark; 2017; 18(2):117-123. PubMed ID: 27935544
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Overexpression of CHD1L is positively associated with metastasis of lung adenocarcinoma and predicts patients poor survival.
    He LR; Ma NF; Chen JW; Li BK; Guan XY; Liu MZ; Xie D
    Oncotarget; 2015 Oct; 6(31):31181-90. PubMed ID: 26360781
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of a Combined RNA Prognostic Signature in Adenocarcinoma of the Lung.
    He SY; Xi WJ; Wang X; Xu CH; Cheng L; Liu SY; Meng QQ; Li B; Wang Y; Shi HB; Wang HJ; Wang ZZ
    Med Sci Monit; 2019 May; 25():3941-3956. PubMed ID: 31132294
    [TBL] [Abstract][Full Text] [Related]  

  • 40. KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma.
    Kadota K; Sima CS; Arcila ME; Hedvat C; Kris MG; Jones DR; Adusumilli PS; Travis WD
    Am J Surg Pathol; 2016 Dec; 40(12):1579-1590. PubMed ID: 27740967
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.